What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection?
作者信息
Younossi Zobair
机构信息
Center for Liver Diseases, Department of Medicine Inova Fairfax Hospital Falls Church VA.
Betty and Guy Beatty Center for Integrated Research Inova Health System Falls Church VA.
出版信息
Clin Liver Dis (Hoboken). 2015 Dec 9;6(5):117-119. doi: 10.1002/cld.509. eCollection 2015 Nov.
Abstract
摘要
相似文献
1
What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection?
Clin Liver Dis (Hoboken). 2015 Dec 9;6(5):117-119. doi: 10.1002/cld.509. eCollection 2015 Nov.
2
Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis.
PLoS One. 2019 Aug 22;14(8):e0218759. doi: 10.1371/journal.pone.0218759. eCollection 2019.
3
'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
Int J Artif Organs. 2018 Jul;41(7):363-370. doi: 10.1177/0391398818763478. Epub 2018 Mar 27.
4
[Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection].
Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):175-178. doi: 10.3760/cma.j.issn.1007-3418.2018.03.004.
5
Experience of a Portuguese Center: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C.
Acta Med Port. 2019 Mar 29;32(3):189-194. doi: 10.20344/amp.10655.
6
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.
Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.
7
Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
Int J Artif Organs. 2018 Jun;41(6):306-318. doi: 10.1177/0391398818762358. Epub 2018 Mar 29.
8
[Selection of direct-acting antiviral agents for chronic hepatitis C infection].
Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):169-172. doi: 10.3760/cma.j.issn.1007-3418.2018.03.002.
9
Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents.
F1000Res. 2016 Feb 26;5:223. doi: 10.12688/f1000research.7970.3. eCollection 2016.
10
[Consensus on management of drug-drug interaction with direct-acting antiviral agents in chronic hepatitis C].
Zhonghua Gan Zang Bing Za Zhi. 2018 Jul 20;26(7):481-488. doi: 10.3760/cma.j.issn.1007-3418.2018.07.001.
引用本文的文献
1
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Hepatology. 2018 Jul;68(1):349-360. doi: 10.1002/hep.29721.
本文引用的文献
1
Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?
Clin Gastroenterol Hepatol. 2015 Nov;13(12):2166-72. doi: 10.1016/j.cgh.2015.07.015. Epub 2015 Jul 17.
2
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
J Hepatol. 2015 Aug;63(2):337-45. doi: 10.1016/j.jhep.2015.03.014. Epub 2015 Mar 17.
3
The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.
Clin Infect Dis. 2015 Jul 15;61(2):157-68. doi: 10.1093/cid/civ220. Epub 2015 Mar 16.
4
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Ann Intern Med. 2015 Mar 17;162(6):407-19. doi: 10.7326/M14-1152.
5
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
Ann Intern Med. 2015 Mar 17;162(6):397-406. doi: 10.7326/M14-1336.
6
Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.
Hepatology. 2015 May;61(5):1471-8. doi: 10.1002/hep.27757. Epub 2015 Mar 23.
7
Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease.
Hepatology. 2015 Jun;61(6):1860-9. doi: 10.1002/hep.27736. Epub 2015 Mar 16.
8
Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
Hepatology. 2015 Jun;61(6):1798-808. doi: 10.1002/hep.27724. Epub 2015 Mar 18.
9
Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
Aliment Pharmacol Ther. 2015 Mar;41(6):544-63. doi: 10.1111/apt.13081. Epub 2015 Jan 26.
10
Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens.
Aliment Pharmacol Ther. 2015 Mar;41(6):497-520. doi: 10.1111/apt.13090. Epub 2015 Jan 23.
Zotero 插件